News | Stents Bifurcation | March 31, 2017

Tryton Medical Announces First U.S. Commercial Case with Tryton Side Branch Stent

Patient with coronary bifurcation lesion involving large side branch treated with first dedicated bifurcation stent to receive regulatory approval in the U.S.

Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center

March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was completed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City. The device was used to treat a coronary bifurcation lesion involving a large side branch (appropriate for a ≥2.5mm stent) in a procedure performed by Martin Leon, M.D., director of the Center for Interventional Vascular Therapy, and Ajay Kirtane, M.D., SM, director of the Cardiac Catheterization Laboratory.

Watch a VIDEO demonstration of the deplyment for the Tryton Dedicated Bifurcation Stent.

pproximately 20-30 percent of all patients undergoing percutaneous coronary interventions (PCI) to open blocked arteries have a bifurcation lesion. The Tryton Side Branch Stent recently became the first dedicated bifurcation stent to receive regulatory approval in the United States. Tryton has signed a strategic distribution agreement with Cardinal Health enabling Cordis, its interventional vascular business, to be the exclusive distributor of the Tryton Side Branch Stent in the U.S.

The Tryton Side Branch Stent System is built using proprietary Tri-Zone technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

Read the article "FDA Clears First Dedicated Coronary Bifurcation Stent."

For more information: www.trytonmedical.com

Related Content

ACC 2018 Late-Breaking Trials Announced
News | ACC| January 23, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Videos | ACC| April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
ACC.17 late breaking trial presentations, ACC late-breakers,  American College of Cardiology late breaking studies
Feature | ACC| March 22, 2017
Here is a list of the American College of Cardiology (ACC) 2017 annual meeting late-breaking clinical trials presente
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Videos | ACC| April 25, 2016
MD Buyline market analyst Jon Brubaker explained the new technology and trends he saw on the show floor at ACC.16. 
Videos | ACC| April 25, 2016
Michael Jaff, M.D., medical director of Massachusetts General Hospital’s Fireman Vascular Center, explains the curren
Videos | ACC| April 15, 2016
DAIC Editor Dave Fornell takes a tour of some of the trends and interesting new technologies from the vendor booths o
Videos | ACC| April 15, 2016
MDbuyline clinical analyst Tom Watson, BS, RCVT, explains the new hemodynamic system technology trends at ACC.16.
ACC late breakers
News | ACC| February 09, 2016
The following are the late-breaking clinical trial presentations presented at the 2016 American College of Cardiology

Photo courtesy of Vital Images

News | ACC| December 22, 2015
December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle facto
Overlay Init